JP7825273B2 - 淋菌感染症に対する免疫原性タンパク質 - Google Patents

淋菌感染症に対する免疫原性タンパク質

Info

Publication number
JP7825273B2
JP7825273B2 JP2022530318A JP2022530318A JP7825273B2 JP 7825273 B2 JP7825273 B2 JP 7825273B2 JP 2022530318 A JP2022530318 A JP 2022530318A JP 2022530318 A JP2022530318 A JP 2022530318A JP 7825273 B2 JP7825273 B2 JP 7825273B2
Authority
JP
Japan
Prior art keywords
nhba
gonorrhoeae
protein
isolated
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503963A (ja
JP2023503963A5 (https=
Inventor
セイブ，ケイト
エフゲニー，セムチェンコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904450A external-priority patent/AU2019904450A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of JP2023503963A publication Critical patent/JP2023503963A/ja
Publication of JP2023503963A5 publication Critical patent/JP2023503963A5/ja
Priority to JP2025171896A priority Critical patent/JP2026021348A/ja
Application granted granted Critical
Publication of JP7825273B2 publication Critical patent/JP7825273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
JP2022530318A 2019-11-25 2020-11-20 淋菌感染症に対する免疫原性タンパク質 Active JP7825273B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171896A JP2026021348A (ja) 2019-11-25 2025-10-10 淋菌感染症に対する免疫原性タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904450A AU2019904450A0 (en) 2019-11-25 Immunogenic protein against gonococcal infection
AU2019904450 2019-11-25
PCT/AU2020/051257 WO2021102505A1 (en) 2019-11-25 2020-11-20 Immunogenic protein against gonococcal infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171896A Division JP2026021348A (ja) 2019-11-25 2025-10-10 淋菌感染症に対する免疫原性タンパク質

Publications (3)

Publication Number Publication Date
JP2023503963A JP2023503963A (ja) 2023-02-01
JP2023503963A5 JP2023503963A5 (https=) 2023-11-28
JP7825273B2 true JP7825273B2 (ja) 2026-03-06

Family

ID=76128579

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530318A Active JP7825273B2 (ja) 2019-11-25 2020-11-20 淋菌感染症に対する免疫原性タンパク質
JP2025171896A Pending JP2026021348A (ja) 2019-11-25 2025-10-10 淋菌感染症に対する免疫原性タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171896A Pending JP2026021348A (ja) 2019-11-25 2025-10-10 淋菌感染症に対する免疫原性タンパク質

Country Status (10)

Country Link
US (1) US12479892B2 (https=)
EP (1) EP4065595A4 (https=)
JP (2) JP7825273B2 (https=)
KR (1) KR20220152402A (https=)
CN (1) CN115348968A (https=)
AU (1) AU2020390430A1 (https=)
BR (1) BR112022010167A2 (https=)
CA (1) CA3162559A1 (https=)
MX (1) MX2022006299A (https=)
WO (1) WO2021102505A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004729A (es) * 2020-10-23 2023-06-29 Omvax Inc Composiciones y metodos de vacunacion contra neisseria gonorrhoeae.
JP2024526293A (ja) * 2021-07-05 2024-07-17 エヴァクシオン・バイオテック・アクティエセルスカブ 淋菌を標的とするワクチン
WO2025196270A1 (en) 2024-03-22 2025-09-25 Limmatech Biologics Ag Outer membrane vesicle vaccines for the prevention of n. gonorrhoeae and methods of making and using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522319A (ja) 2014-07-17 2017-08-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
JP2019532035A (ja) 2016-09-02 2019-11-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047238A (en) 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5811105A (en) 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
EP1962961B1 (en) 2005-11-29 2013-01-09 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
MX2017015404A (es) * 2015-06-02 2018-05-22 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
CN106606775A (zh) 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017522319A (ja) 2014-07-17 2017-08-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
JP2019532035A (ja) 2016-09-02 2019-11-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chung G.T. et al.，Accession No. B4RQT3, Definition: SubName: Full=GNA2132，Database UniProt [online]，2008年，インターネット <URL: https://rest.uniprot.org/unisave/B4RQT3?format=txt&versions=1>，23-SEP-2008 uploaded [検索日 2024.11.06]
Clinical Infectious Diseases，2019年，Vol.69, No.7，pp.1101-1111
JOURNAL OF BACTERIOLOGY，2008年，Vol.190, No.17，pp.6035-6036
JOURNAL OF BIOLOGICAL CHEMISTRY，2011年，Vol.286, No.48，pp.41767-41775

Also Published As

Publication number Publication date
EP4065595A4 (en) 2023-12-20
EP4065595A1 (en) 2022-10-05
US20230181709A1 (en) 2023-06-15
KR20220152402A (ko) 2022-11-15
JP2023503963A (ja) 2023-02-01
US12479892B2 (en) 2025-11-25
CN115348968A (zh) 2022-11-15
MX2022006299A (es) 2023-01-19
AU2020390430A1 (en) 2022-07-14
BR112022010167A2 (pt) 2022-08-09
JP2026021348A (ja) 2026-02-10
CA3162559A1 (en) 2021-06-03
WO2021102505A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
EP2265640B1 (en) Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
CN102834410B (zh) 改性的h因子结合蛋白（fhbp）及其使用方法
JP5622344B2 (ja) Ｎｅｉｓｓｅｒｉａ配合組成物
CN101107007B (zh) 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP2026021348A (ja) 淋菌感染症に対する免疫原性タンパク質
CN103124737A (zh) 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗
CN105431167A (zh) 非天然发生因子h结合蛋白(fhbp)及其使用方法
US20140341895A1 (en) PSEUDOMONAS AERUGINOSA OprM EPITOPES FOR USE IN DIAGNOSTICS AND THERAPEUTICS
US8962801B2 (en) Neisseria porin proteins
HK40072982A (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof
HK40072982B (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof
Lavender Complement Factor H Related proteins and their biological role during bacterial infection
HK1186476A (en) Recombinant neisseria meningitidis por a porin proteins
HK1179980B (en) Factor h binding proteins (fhbp) with altered properties and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260216

R150 Certificate of patent or registration of utility model

Ref document number: 7825273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150